Influenza and Other Respiratory Virus Weekly Activity Report, June 13, 2009, revised Week 23

Weekly report of the Iowa Influenza Surveillance Network produced by the Iowa Department of Public Health.

Evaluación de la población de concha de abanico en la Bahía de Independencia, Pisco, Perú. 23 de setimebre-9 de octubre de 1987

El presente informe tiene por objetivo principal conocer, el estado poblacional y biológico de la concha de abanico y algunos aspectos físicos-químicos del agua de la Bahía Independencia durante setiembre de 1987.

The OCBI Tipping Point, August 23, 2007, Vol. 1, no.3

This is the weekly e-Newsletter called “The OCBI Tipping Point.” We hope that you find it very informative as we explore all possibilities to keep our constituency and the general public informed about all matters that affect Blacks in the state of Iowa.

Quand Jésus fait le procès des juifs: Matthieu 23 et l'antijudaïsme

(Résumé de l'ouvrage) Les 23 et 24 novembre 1996, s'est déroulé à la Faculté de théologie de Toulouse, à l'occasion de la remise d'un volume d'hommages à Simon Légasse, un colloque intitulé « Procès de Jésus, procès des Juifs ? » Le titre du colloque mérite une explication. Le point d'interrogation exprime tout à la fois le questionnement et l'incrédulité devant la possibilité de s'appuyer sur les récits rapportant le procès de Jésus pour mettre en accusation les Juifs. L'association des deux expressions rappelle que l'histoire des chrétiens n'a que trop souvent démontré que le procès de Jésus pouvait servir à justifier des pratiques antijudaïques et antisémites. Au terme du colloque, deux enseignements se dégagent avec force : d'abord que l'ignorance est toujours coupable. Les chrétiens doivent connaître leur dette envers le peuple juif et cesser de caricaturer leur interprétation de la Bible ou de faire comme si le judaïsme s'était éteint à l'avènement du christianisme. Ensuite, que la médiation de la critique historique est essentielle, car les Écritures, Parole de Dieu, sont aussi parole humaine et l'on s'expose à de dangereuses dérives si l'on oublie de tenir compte de leur historicité.

Recurrent deletions and reciprocal duplications of 10q11.21q11.23 including CHAT and SLC18A3 are likely mediated by complex low-copy repeats.

We report 24 unrelated individuals with deletions and 17 additional cases with duplications at 10q11.21q21.1 identified by chromosomal microarray analysis. The rearrangements range in size from 0.3 to 12 Mb. Nineteen of the deletions and eight duplications are flanked by large, directly oriented segmental duplications of >98% sequence identity, suggesting that nonallelic homologous recombination (NAHR) caused these genomic rearrangements. Nine individuals with deletions and five with duplications have additional copy number changes. Detailed clinical evaluation of 20 patients with deletions revealed variable clinical features, with developmental delay (DD) and/or intellectual disability (ID) as the only features common to a majority of individuals. We suggest that some of the other features present in more than one patient with deletion, including hypotonia, sleep apnea, chronic constipation, gastroesophageal and vesicoureteral refluxes, epilepsy, ataxia, dysphagia, nystagmus, and ptosis may result from deletion of the CHAT gene, encoding choline acetyltransferase, and the SLC18A3 gene, mapping in the first intron of CHAT and encoding vesicular acetylcholine transporter. The phenotypic diversity and presence of the deletion in apparently normal carrier parents suggest that subjects carrying 10q11.21q11.23 deletions may exhibit variable phenotypic expressivity and incomplete penetrance influenced by additional genetic and nongenetic modifiers.

Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance.

The biological activity of interleukin (IL)-2 and other cytokines in vivo can be augmented by binding to certain anti-cytokine monoclonal antibodies (mAb). Here, we review evidence on how IL-2/anti-IL-2 mAb complexes can be used to cause selective stimulation and expansion of certain T-cell subsets. With some anti-IL-2 mAbs, injection of IL-2/mAb complexes leads to expansion of CD8 T effector cells but not CD4 T regulatory cells (Tregs); these complexes exert less adverse side effects than soluble IL-2 and display powerful antitumor activity. Other IL-2/mAb complexes have minimal effects on CD8 T cells but cause marked expansion of Tregs. Preconditioning mice with these complexes leads to permanent acceptance of MHC-disparate pancreatic islets in the absence of immunosuppression.

Documents et pièces diverses, en majeure partie originaux, conservés jadis dans le TRESOR DES CHARTES DE LORRAINE. — Nombreux sceaux. — Voy. l'analyse détaillée de la plupart de ces pièces dans l'Inventaire de Dufourny (Bibl. nat., ms. fr. 4880-4886 ; Bibl. de Nancy, mss. 754-765). On ne relève ici que les pièces qui n'y figurent pas. XLV — Portefeuille-layette 23 b (1344-1622)

Metz évêché ; Bulles et autres pièces, n os 1-10, 12-14, 17-24, 26-36. Voy. Bibl. nat., ms. fr. 4883, pp. 7789-7800 ; Bibl. de Nancy, ms. 763, 1 re partie, pp. 167 et 168. — Voy. ms. fr. 4883, pp. 7761-7789.

Fiscal Update, December 23, 1997

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Fiscal Update, December 23, 1997

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Fiscal Update, February 23, 1998

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Fiscal Update, February 23, 1998

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

Effects of an interleukin-15 antagonist on systemic and skeletal alterations in mice with DSS-induced colitis.

Inflammatory bowel diseases are commonly complicated by weight and bone loss. We hypothesized that IL-15, a pro-inflammatory cytokine expressed in colitis and an osteoclastogenic factor, could play a central role in systemic and skeletal complications of inflammatory bowel diseases. We evaluated the effects of an IL-15 antagonist, CRB-15, in mice with chronic colitis induced by oral 2% dextran sulfate sodium for 1 week, followed by another 1% for 2 weeks. During the last 2 weeks, mice were treated daily with CRB-15 or an IgG2a control antibody. Intestinal inflammation, disease severity, and bone parameters were evaluated at days 14 and 21. CRB-15 improved survival, early weight loss, and colitis clinical score, although colon damage and inflammation were prevented in only half the survivors. CRB-15 also delayed loss of femur bone mineral density and trabecular microarchitecture. Bone loss was characterized by decreased bone formation, but increased bone marrow osteoclast progenitors and osteoclast numbers on bone surfaces. CRB-15 prevented the suppression of osteoblastic markers of bone formation, and reduced osteoclast progenitors at day 14, but not later. However, by day 21, CRB-15 decreased tumor necrosis factor α and increased IL-10 expression in bone, paralleling a reduction of osteoclasts. These results delineate the role of IL-15 on the systemic and skeletal manifestations of chronic colitis and provide a proof-of-concept for future therapeutic developments.